Analysts expect Danaher to report Q1 revenue of approximately $6.00 billion and EPS of $1.94, while the current stock price of $194.75 reflects a significant discount to the $255.80 average analyst price target.
Investors are primarily focused on the recovery and growth trajectory of bioprocessing core revenue, which serves as a critical indicator for the health of the broader life sciences tools sector.
Management recently guided for full-year core revenue growth of 3% to 6%, underpinned by high-single-digit demand for bioprocessing consumables and monoclonal antibodies. Furthermore, market participants are closely monitoring the initial synergy realization from the $9.9 billion acquisition of Masimo Corporation, which closed earlier this year.